Boehringer Ingelheim Discontinues NPY2 Obesity Drug Development with Gubra, Focuses on Triple-Agonist Candidate

Discontinuation of NPY2 Project:
Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2) agonist, a joint project with Gubra aimed at treating obesity.

Continued Collaboration:
Despite this discontinuation, the partnership between Boehringer Ingelheim and Gubra remains intact, with ongoing projects such as the Phase 1 trial for BI 3034701, a novel triple-agonist peptide drug candidate for obesity.

BI 3034701 Phase 1 Trial: The Phase 1 trial for BI 3034701, initiated in July 2024, aims to assess the safety, tolerability, and pharmacokinetics of the drug. It includes two parts:
one focusing on healthy men and another on both men and women with overweight or obesity.

Potential Impact:
The discontinuation of the NPY2 project has led to a 13% drop in Gubra's shares, but the company emphasizes that this decision will not affect their broader collaboration with Boehringer Ingelheim.

Focus on Triple-Agonist:
Boehringer Ingelheim and Gubra are optimistic about the potential of BI 3034701, which targets three receptors associated with weight loss, offering a new approach to treating obesity.